Recruiting studies: Type 1 Primary Hyperoxaluria

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD
Phase 2 · 18 location(s) · Dicerna Pharmaceuticals, Inc., a Novo Nordisk company · NCT04580420 Clinical Exploration Study of YOLT-203 in the Treatment of Type 1 Primary Hyperoxaluria (PH1)
EARLY_Phase 1 · 1 location(s) · RenJi Hospital · NCT06511349 Rare Kidney Stone Consortium Biobank
Phase N/A · 1 location(s) · Mayo Clinic · NCT02026388 Prospective Research Rare Kidney Stones (ProRKS)
Phase N/A · 11 location(s) · Mayo Clinic · NCT02780297 Phase 1/2 Study of ABO-101 in Primary Hyperoxaluria Type 1 (redePHine)
Phase 1/Phase 2 · 7 location(s) · Arbor Biotechnologies · NCT06839235 National Registry of Rare Kidney Diseases
Phase N/A · 1 location(s) · UK Kidney Association · NCT06065852 Retrospective and Prospective Follow-up of Patients With Primary Hyperoxaluria Type 1 Treated With Lumasiran in France.
Phase N/A · 7 location(s) · Hospices Civils de Lyon · NCT06225882

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.